CIK 0001231457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- 4 Planned sale Director sold 10,000 shares at $2.98 ($29,801)
- 4 Open-market sale Chief Scientific Officer sold 605 shares at $2.97 ($1,798)
- 4 Open-market sale Chief Technical Officer sold 605 shares at $2.97 ($1,799)
- 4 Open-market sale President and CEO sold 2,798 shares at $2.94 ($8,226)
- 4 Open-market sale Head of Regulatory sold 270 shares at $2.98 ($804)
- 4 Open-market sale Head of Regulatory sold 585 shares at an average $2.46 ($1,437)
- 4 Open-market sale Chief Technical Officer sold 906 shares at $2.42 ($2,193)
- 4 Open-market sale SVP, Clinical Development sold 906 shares at $2.42 ($2,193)
- 4 Open-market sale President and CEO sold 3,582 shares at $2.42 ($8,668)
- 4 Planned sale Director sold 10,000 shares at $2.90 ($28,957)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale SVP, Clinical Development sold 4,192 shares at an average $3.82 ($16,032)
- 4 Open-market sale President and CEO sold 17,182 shares at an average $3.86 ($66,370)
- 4 Open-market sale Chief Technical Officer sold 3,706 shares at an average $3.88 ($14,361)
- 4 Open-market sale Head of Regulatory sold 2,332 shares at an average $3.75 ($8,740)
- 4 Planned sale Director sold 10,000 shares at $5.00 ($50,008)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Head of Regulatory acquired 10,000 shares (grant or award)
Page 2 of 10 · 190 filings